Statements made in this news release that are not historical facts , including statements concerning future securities registrations or other filings with the U.S. Securities and Exchange Commission ( " SEC " ) , future treatment of patients with GBM using DCVax ( R ) -Brain , and other future clinical trials , are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Words such as " may , " " expects , " " believes , " " intends , " " anticipates , " and similar expressions are intended to identify forward-looking statements . Actual results may differ materially from those projected in any forward-looking statement . Specifically , there are a number of important factors that could cause actual results to differ materially from those anticipated , such as the SEC 's review and evaluation of securities registrations or other filings , the Company 's ability to raise additional capital , risks related to the Company 's ability to enroll patients in its clinical trials and complete the trials on a timely basis , uncertainties related to the clinical trials process , uncertainties about the timely performance of third parties , and uncertainties about whether the Company 's products will demonstrate safety and efficacy . Additional information on these and other factors , which could affect the Company 's results , is included in its SEC filings and the Risk Factors section of the Form S-1 that the Company is preparing to file . Finally , there may be other factors not mentioned above or included in the Company 's SEC filings or upcoming Form S-1 that may cause actual results to differ materially from those projected in any forward-looking statement . You should not place undue reliance on any forward-looking statements . The Company assumes no obligation to update any forward-looking statements as a result of new information , future events or developments , except as required by securities laws .